Oncocyte CORP

Insight Molecular Diagnostics reports progress on its GraftAssureDx FDA submission and positive developments in Medicare reimbursement, alongside Q2 2026 financial results.

Insight Molecular Diagnostics Inc. announced its Q1 2026 financial results, highlighting progress in commercializing its GraftAssureDx transplant rejection monitoring test and advancements in clinical trial engagement.

Insight Molecular Diagnostics Inc. amends a prior 8-K filing to correctly disclose a Specimen Collection Agreement with Quest Diagnostics for its GraftAssureCoreTM test.

Insight Molecular Diagnostics Inc. filed an 8-K to correct a clerical error in the Third Amended and Restated Bylaws previously incorporated into its 2025 Annual Report.

Insight Molecular Diagnostics Inc. submitted its GraftAssureDx kidney transplant rejection test for FDA review and reported Q4 and full-year 2025 financial results.

Insight Molecular Diagnostics Inc. has partnered with Quest Diagnostics for specimen collection services related to its GraftAssureCore test.

Insight Molecular Diagnostics Inc. (IMDX) filed its Q2 2026 Form 10-Q, revealing a substantial decrease in net revenue and an increase in operating expenses, leading to a wider net loss.

Insight Molecular Diagnostics Inc. reported a reduced net loss for Q3 2025, driven by increased revenue and a significant capital raise, while advancing its diagnostic pipeline and expanding its global footprint.

Insight Molecular Diagnostics Inc. reports significant revenue growth and a strengthened cash position following a successful capital raise, despite continued operating losses.

Oncocyte Corporation's Q1 2025 net revenue increased significantly due to growth in Pharma Services, while the net loss decreased compared to the same period last year.

Oncocyte Corporation reported a net loss of $13.5 million in Q3 2024, a 108% increase from the same period last year, as the company pivots towards commercializing its transplant diagnostic tests.

Oncocyte Corporation's Q2 2024 results show a decrease in revenue and a significant increase in net loss, alongside strategic changes and a focus on commercializing transplant products.

Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $50.2 million for 2025, narrowing losses while advancing its core transplant diagnostics and securing significant capital for future growth.

Oncocyte Corporation's 2024 10-K filing reveals a year of strategic realignment, marked by increased operating losses and a focus on commercializing transplant diagnostic tests.

Oncocyte Corporation's 10-K filing provides a detailed overview of its common and preferred stock, outstanding warrants, and the regulatory environment it operates within.

Insight Molecular Diagnostics Inc. Director Lou Silverman reported a disposition of 7,700 common shares on July 1, 2026, to cover tax withholding obligations.

Andrew J. Last, a Director at Insight Molecular Diagnostics Inc., reported a transaction involving the disposition of 7,700 shares of common stock on July 1, 2026, to cover tax withholding obligations.

Director Andrew Arno reports a transaction involving the withholding of shares for tax purposes and indirect beneficial ownership of additional shares in Insight Molecular Diagnostics Inc.

Director Lou Silverman acquired 26,943 shares of Insight Molecular Diagnostics Inc. common stock via a restricted stock unit grant.

Director Andrew J. Last acquired 26,943 shares of Insight Molecular Diagnostics Inc. through a restricted stock unit grant.

Director Andrew Arno acquired 32,331 restricted stock units in Insight Molecular Diagnostics Inc. on June 11, 2026.

Oncocyte Corporation has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Oncocyte Corporation's 2025 Annual Meeting of Shareholders will be held virtually on June 27, 2025, to vote on director elections, accounting firm ratification, executive compensation, and an equity incentive plan amendment.

Oncocyte Corporation is asking shareholders to approve an amendment and restatement of its 2018 Equity Incentive Plan to increase the number of shares available for issuance and make other changes to the plan's administration.

Oncocyte Corporation will hold its 2024 Annual Meeting of Shareholders virtually on June 28, 2024, to vote on director elections, ratification of the accounting firm, and executive compensation.

Oncocyte Corporation has filed an S-1 registration statement with the SEC to allow selling stockholders to resell up to 10,606,632 shares of common stock acquired through a recent private placement and associated warrants.

Broadwood Partners, L.P. has increased its beneficial ownership in Insight Molecular Diagnostics Inc. to 39.7% following a series of open-market share purchases.

Broadwood Partners increased its beneficial ownership in Insight Molecular Diagnostics Inc. to 37.4% through a $3 million registered direct offering.

Broadwood Capital and its affiliates have significantly increased their beneficial ownership in Oncocyte Corp to 40.2% through a $10.6 million private placement and registered direct offering at $2.05 per share.

AWM Investment Company, Inc. has filed an amended Schedule 13G, disclosing a 9.99% beneficial ownership stake in Oncocyte Corp as of March 31, 2025.

Bio-Rad Laboratories, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 9.66% of Oncocyte Corporation's common shares as of February 10, 2025.

AWM Investment Company, Inc. has filed an amended Schedule 13G, disclosing a 7.5% passive ownership stake in Oncocyte Corp. as of December 31, 2024.